Key result
In-series implantation of a second transcatheter heart valve successfully treated severe TAVR regurgitation while avoiding sinus sequestration in two high-risk cases.
Why the study?
Redo TAVR may pose the risk of coronary flow obstruction.
Does in-series implantation of a second transcatheter heart valve prevent sinus sequestration in patients with severe TAVR regurgitation undergoing redo TAVR?
Case Report (n=2)
Does in-series implantation of a second transcatheter heart valve prevent sinus sequestration in patients with severe TAVR regurgitation undergoing redo TAVR?
In-series implantation of a second transcatheter heart valve can be a successful bailout strategy to avoid sinus sequestration during redo TAVR.
May offer bailout option in high-risk redo TAVR; leaves open need for prospective validation of safety and durability.
Redo transcatheter aortic valve replacement (TAVR) may pose the risk of coronary flow obstruction. We report 2 cases of severe TAVR regurgitation due to different physiopathological mechanisms in which TAVR-in-TAVR could be at high risk for sinus sequestration. Both cases were successfully treated by in-series implantation of a second transcatheter heart valve, thus avoiding sinus sequestration. (Level of Difficulty: Intermediate.)
No takes yet. Share an insight, caveat, or question.
Casenghi et al. (2021) conducted a case report in Severe TAVR regurgitation at high risk for sinus sequestration (n=2). In-series implantation of a second transcatheter heart valve was evaluated on Successful treatment avoiding sinus sequestration. In-series implantation of a second transcatheter heart valve successfully treated severe TAVR regurgitation while avoiding sinus sequestration in two high-risk cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: